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Managed care groups, physician management organiza-
tions, and independent practice associations in the United
States are increasingly seeing formulary submission
guidelines as a key management tool for cost and quality
control within health systems. The purpose of this work-
shop is to describe the process of guideline development,
the analytical and evaluative standards required from
those making submissions and the implementation of
guidelines within managed care health systems. The focus
is on the guidelines recently put in place by Blue Cross
Blue Shield of Colorado, Nevada, and New Mexico (with
over 0.5 million members), which were developed at the
University of Colorado, and similar guidelines in the pro-
cess of development for the Academy of Managed Care
Pharmacy in Washington, DC. Of particular importance
in this presentation are the analytical and evaluative stan-
dards required in the guidelines. While the guidelines are
similar in a number of respects to the revised November
1995 Australian guidelines, the central requirement is for
projections to be made of the net cost and outcomes im-
pact on a treating population from the introduction of a
new drug or therapy intervention in disease or treatment
areas. This is described as a systems impact assessment,
which is quite different from the analytical focus of tradi-
tional pharmaceutical economics. Rather than base for-
mulary decisions on implications drawn from synthetic
decision models, the guidelines ask for cost and outcome
impact assessments which are, in principle, verifiable.
This means they can serve as a basis for monitoring
health impact assessments of set targets and in the con-
text of disease or care management interventions.
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Pharmacoeconomic data are extremely useful for the de-
velopment of optimal treatment strategies in terms of clini-
cal efficacy, safety, and cost of drug therapy. Although sev-
eral pharmacoeconomic trials have been conducted in
Russia, these data are quite scarce in our country. In the
majority of cases, foreign data are the only available sources
of information. The main advantages of these data are
their methodology, design, and modern approaches to data
analyses and interpretation. However, Russian doctors
and health authorities should be very careful in using data
obtained abroad. As far as we are concerned, there are at
least four principal limitations for these data in Russia.
Firstly, variations in epidemiology of given diseases exist
among different countries. Secondly, we see a difference in
drug prices; for instance, cefotaxime (1 g) costs 2.44 USD
in Russia versus 11.7 USD in the US. Thirdly, the costs of
medical service and hospitalization are much less costly in
Russia than in Western countries—the cost per ICU day in
Russia is about 100 USD (Smolensk Regional Hospital),
whereas in the US it is about 1000 USD (Millard Fillmore
Suburban Hospital, Williamsville, NY). This may explain
to some extent the lack of sufficient attention paid by Rus-
sian physicians to the duration of hospitalization. The total
cost of treatment nowadays in Russia predominantly de-
pends on drug therapy cost. Finally, there are differences in
financing sources of health services between countries. The
Russian healthcare system is predominantly funded by the
Government and/or insurance companies. Moreover, there
are often different sources of financing within one region.
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Since 1998, the standardization system in Russia has been
functioning in the public health system, which corresponds
with the state system of standardization and with the inter-
national requirements in this field. This system is to solve
the following major problems: 1) to assure that citizens
shall exercise their rights to generally available free of
charge medical care of high quality; 2) to provide the com-
pulsory health insurance system in Russia with a standard-
izing base; and 3) to provide the certification and quality
assessment system to be set up in the health public system
with standards and specifications. At the first stage of de-
velopment, 16 groups of standardization objects were iden-
tified and the basic principles formulated. The most impor-
tant principles are a consensuality principle (i.e., a mutual
agreement between all the parties engaged in the develop-
ment and use of standards), an actuality principle (i.e.,
compliance of the elaborated documents with legislative
and other international and state requirements), and a com-
plexity principle (i.e., solution of problems of standard-
ization in all spheres of citizen healthcare by uniform
methods). At the second stage, a working program on the
establishment and development of a public health stan-
dardization system in Russia was worked out and ap-
proved, highlighting the priorities of work, defining a list of
priority regulatory documents, and executing this work.
Particular emphasis is placed on a group of system-forming
documents: a group of documents that regulate the terms,
conditions, and quality of the medical services rendered;
and a group of documents pertaining to drug provision,
medical equipment, informational technologies, etc. Assim-
ilation of the results of new studies in pharmacological
economy and evidence-based medicine will be a very im-
portant element of development of the documents regulat-
ing the rendering of medical services. The specialists of the
pharmaceutical company Rhône-Poulenc, whose collabora-
tion helps to introduce mathematical programs and infor-
mational technologies into the development of a program
